Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376470 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(10 years from now) | |
US9763885 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(10 years from now) |
Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 23 March, 2021
Treatment: Treatment of hyperlipidemia
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic